FMP
TScan Therapeutics, Inc.
TCRX
NASDAQ
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
7.69 USD
-0.06 (-0.78%)
About
ceo
Dr. Gavin MacBeath Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://www.tscan.com
exchange
NASDAQ
Description
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients ...
CIK
0001783328
ISIN
US89854M1018
CUSIP
89854M101
Address
830 Winter Street
Phone
857 399 9500
Country
US
Employee
154
IPO Date
Jul 16, 2021
Summary
CIK
0001783328
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
89854M101
ISIN
US89854M1018
Country
US
Price
7.69
Beta
0.86
Volume Avg.
163.66k
Market Cap
335.33M
Shares
-
52-Week
1.62-9.0
DCF
0
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-5.7
P/B
-
Website
https://www.tscan.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest TCRX News
It looks like there's no news available.
